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A BST R AC T   
 
Aim: Thyroid cancers are the most commonly encountered endocrine system malignancies.  The incidence 
continues to rise worldwide. Our aim in this study is to investigate the frequency and histopathological 
subtypes of thyroid cancer in our clinic. 
Methods: The present study was conducted with 3614 patients who were followed up in our endocrinology 
and general surgery clinic and operated with the diagnosis of multinodular and/or nodular goiter between 2015 
and 2021. The histopathological types and information of patients diagnosed with thyroid cancer were obtained 
retrospectively from the pathology reports. Among the patients included in the study, a total of 570 people 
who were reported to have thyroid cancer due to histopathology were included in the study. 
Results: The data of a total of 3614 biopsy reports were examined for the study. Among these patients, 570 
(421 females, 149 males) were operated and whose pathology reports were accessed were included in the 
study. The mean age of the patients was 49.12±10.4 years. As a result of the operations, malign postoperative 
tissue histopathology was 98.9% (n=564), and uncertain malignancy potential was reported to be 1.0% (n=6). 
In our study, the histopathological distribution of thyroid cancers was as follows; thyroid papillary cancer 
89.4% (n=510), follicular cancer 7.3% (n=42), medullary cancer 2.1% (n=12), and malignancy potential 
uncertain 1.0% (n=6). 
Conclusion: The results of our study suggest that thyroid cancers are more common in women in our country, 
in parallel with the similar rates reported in the literature, with the increase worldwide. 
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Introduction 
Thyroid Cancer (TC) incidence is increasing 
rapidly; however, the mortality rate remains 
stable. There are five main histological types of 
TC: papillary, follicular, poorly differentiated, 
anaplastic (the most aggressive form), and 
medullary thyroid cancer [1,2]. The prevalence 
of TC is approximately three times more in 
women than in men, and it is the fifth most 
common cancer in women [3]. According to the 
health data of 2015, TCs represent 12.1% of all 
cancers in women and 2.7% of all cancers in 
men in Turkey [4]. TC is the most common 
endocrine malignancy, constituting 2.9% of all 
new cancer cases in the USA. These cancers 
have an excellent prognosis with a 5-year 
survival rate of 98.3%. Differentiated thyroid 
cancers originate from follicular epithelial cells 
and account for more than 90% of all the 
thyroid malignancies [5,6]. 
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The prevalence of TC is high in areas where 
nodular goiter is endemic. In this respect, it is 
important that Turkey is an endemic goiter 
region. TCs are 3-4 times more common in 
women than in men [7]. The purpose of the 
present study was to investigate the prevalence 
of TCs and histopathological cancer types in 
our clinic.  
 
Materials and methods 
A total of 3614 patients who were followed up 
in our Endocrinology and General Surgery 
Clinic diagnosed with multinodular and/or 
nodular goiter between 2015 and 2021 were 
selected to include in the present study. Among 
these patients, 570 people reported TCs in 
pathology reports and were included in the 
study. The demographic characteristics, 
preoperative  
Thyroid fine needle biopsy (TFNABx), and 
postoperative histopathology reports were 
collected from patient files and electronic 
records. The Clinical Research Ethics 
Committee approval of Medicana International 
Samsun hospital was obtained with the decision 
at the meeting with the number 7133 - 1 
(20.04.2020-08). The study was conducted in 
line with ethical rules. 
Among the patients, those with follicular 
neoplasia, suspected malignancy, and 
malignant cytological characteristics were 
operated on. Some of the patients had benign 
results in biopsies and were operated on 
because of aesthetic concerns, compression 
findings, and other reasons. Among these 
patients, 570 people reported to have TCs in 
pathology reports were included in the study. 
Statistical analyses 
The Chi-Square was used in the categorical 
data, and the Non-Paired Students t-Test was 
used to compare the continuous variables. The 
average number of positive criteria in malignant 
lesions was compared with the Non-Paired 
Students t-Test. One-Way ANOVA and 
Multiple t-Tests were used for the comparison 
of TC subtypes. Statistical significance level 
was taken as p <0.05. 
 
Results  
The data of patients who underwent a total of 
3.614 biopsies were analyzed for the study. 
Among these patients, 570 (421 women, 149 
men), who were operated and whose pathology 
results were available, were included in the 
study. The mean age of the patients was 49.12 
± 10.4. The demographic characteristics of the 














Among the 570 patients who were included in 
the study, the preoperative TFNABx results 
were benign in 0.1% (n = 1), Follicular, Hurthle 
cell neoplasia or suspected in 2.8% (n = 16), 
suspected malignancy in 46.4% (n = 265), and 
malignant in 50.5% (n = 288) patients (Figure 
1A). Postoperative tissue histopathology was 
reported as malignant in 98.9% (n = 564), and 
with unclear malignancy potential in 1.0% (n = 
6) patients. In our study, the histopathological 
distribution of the thyroid cancer was thyroid 
papillary cancer in 89.4% (n = 510) (Figure 
1B), follicular cancer in 7.3% (n = 42), and 
Table 1. Demographic and hematologic 
characteristics of the cases. 
 
Parameters N 
Gender, Female/Male 421/149 
Age (years)  49,12±10,4 
TSH, mIU/L  2,13±1,5 
Anti-TPO,  IU/mL  121,6±33,9 
Anti-TG, IU/mL  87,2±12,5 
Anti-TPO: Anti-thyroid peroxidase antibody, Anti-TG: 
Anti-thyroglobulin antibody. 
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medullary cancer in 2.1% (n = 12) patients 
(Figure 1C and D). The TFNABx reports of the 
cases and the histopathological distribution of 
the thyroid cancer are shown in Table 2. 
We found that thyroid cancers were most 
common in the 41-50 age group. Half of the 
cancer prevalence was detected in the 31-50 age 
group. The distribution of cancers according to 
age is shown in Table 3. We found that the 
autoimmunity was 24%, and the frequency of 
goiter was 3.8% in women with thyroid 





























autoimmunity and goiter in thyroid cancer 
cases according to gender is shown in Table 4. 
We found the frequency of autoimmunity to be 
30% in our study, and the frequency of goiter 
was 5.9% in thyroid cancers. The prevalence of 
autoimmunity, goiter, and histopathological 
distribution in thyroid cancer is shown in Table 
5. We found the multicentricity rate to be 23.2% 
in thyroid cancer. In thyroid cancer cases, 
cancer histology shows the distribution of 
goiter and autoimmunity. Other pathological 































Table 2. Fine needle biopsy reports and histopathological distribution of thyroid cancers. 




TIIABx  benign, n=1 - 1 - - 
TIIABx  follicular, Hurthle cell 









TIIABx  malignity suspicious, n=265 237 17 8 3 





42 (31/11) 12 (7/5) 6 (4/2) 
TC: Thyroid cancer, TIIABx: Thyroid fine-needle aspiration biopsy, F: female, M: male. 
 
Figure 1. A) Fine needle aspiration biopsy, malignant (consistent with papillary carcinoma). B) Tissue 
histopathology; papillary carcinoma. C) Tissue histopathology; follicular carcinoma. D) 
Immunohistochemically examination, chromogranin A (+); medullary carcinoma. 
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Thyroid cancers make up the most common 
malignancy in the endocrine system and 
account for 3.4% of all cancers diagnosed 
annually on a global scale [8]. It has been 
detected in recent years that the increasing 
incidence of thyroid cancer and over-diagnosis 
has begun to slow down [9]. The rapid increase 
in TC incidence was parallel to the detected 
thyroid nodules, the more common use of 
thyroid ultrasonography, and the increase in the 
incidence of biopsy [10]. 
Thyroid carcinomas were most frequently 
detected in the 41-50 age group in our study. 
We found the prevalence of autoimmunity as 
30%, and the frequency of goiter was 5.9% in 
thyroid cancer cases. The prevalence of 
autoimmunity in women was 24%, and that of 
goiter was 3.8%, consistent with the literature 
data. We also found the multicentricity rate as 
23.2% in thyroid carcinomas. These findings 
are in line with the current literature findings. 
Papillary thyroid carcinoma is the most 
common histological type, which accounts for 
approximately 85-95% of thyroid malignant 
neoplasms. The 10-year survival rate is over 
90% in these cancers. These tumors generally 
have silent biological behavior [11,12]. In 
previous studies, papillary carcinoma was more 
common in women at a rate of 76.40% and 
23.59% in men [13]. In the present study, 
papillary carcinoma subtype was the most 
common histologic type at 89.4% (510/570). 




     18-30              31-40                41-50                   51-60                 61-75  
Follicular carcinoma 6 (1.0) 11 (1.9) 16 (2.6) 7 (1.2) 2 (0.3) 
Papillary carcinoma 52 (9.1) 85 (14.9) 210 (36.8) 113 (19.8) 50 (8.7) 




1 (0.1) 1 (0.1) 2 (0.3) 2 (0.3) - 
 
Table 4. Distribution of autoimmunity and goiter 
according to gender in thyroid cancer cases. 
Histological types 
 
Male Female Ratio 
(Female: 
Male) 
Autoimmune 34 137 4,02:1 
Goiter 12 22 1,8:1 
Thyroid carcinomas 146 424 2,9:1 
 
Table 5: Distribution and frequency of autoimmunity 
in goiter and histopathologic thyroid cancers. 





























Table 6. Pathologic features of the patients with 
thyroid carcinoma. 
Pathologic features Frequency (%) 
Multicentricity  23.2 
Tumor capsule invasion  5.6 
Lymphatic invasion  6.7 
Vascular invasion  6.4 
Extrathyroidal invasion  3.8 
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We showed in this study that it is more common 
in women at a rate of 74.9% (382/510). The rate 
of papillary carcinoma was 37.5% (6/16) in 
cases with TFNABx follicular, Hürthle cell 
neoplasia or suspected malignancies, 89.4% 
(237/265) in patients with suspected 
malignancies, and 92.7% (267/288) in those 
with malignancies. 
Follicular carcinoma represents approximately 
5-10% of thyroid malignancies and can be 
detected at much higher rates, such as 25-40% 
in areas with intense iodine deficiency [14,15]. 
Follicular carcinoma is a more aggressive type 
of thyroid cancer with an increasing prevalence. 
Unlike papillary thyroid cancer, which spreads 
over lymphatics, follicular thyroid cancer is 
more aggressive because it can metastasize 
through vascular invasion [16]. In our study, we 
detected that the Follicular Carcinoma Subtype 
was at a rate of 8.2% (42/570). We showed that 
it is more prevalent in women at a rate of 73.8% 
(31/42). The rate of follicular carcinoma was 
56.2% (9/16) in cases with TFNABx follicular 
carcinoma, Hürthle cell neoplasia, or suspected 
6.4% (17/265) in patients with suspected 
malignancies, and 5.2% (15/288) in those with 
malignancies. 
Medullary thyroid carcinoma is a rare type of 
tumor that originates from thyroid C cells and 
constitutes 2-4% of all malignant thyroid 
tumors. Medullary carcinoma may occur 
sporadically or be inherited as a part of MEN 
Type 2 syndrome [17,18]. In our study, the 
medullary carcinoma subtype was found to be 
2.1% (12/570). It was also shown that it is more 
prevalent in women with a rate of 58.3% (7/12). 
We found that the rate of medullary carcinoma 
was 3.0% (8/265) in those with suspected 
malignancies and 1.3% (4/288) in those with 
malignancies. In previous studies, the “well-
differentiated tumor with uncertain malignant 
potential” term is used for lesions with 
follicular patterns of the thyroid, which cannot 
be diagnosed easily as benign or malignant 
because of the lack of suspicious nuclear 
changes and capsular or vascular invasion. The 
basic reason behind this recommendation is 
that, clinically, such lesions behave benignly 
with an excellent prognosis [19]. In our study, 
it was found that the uncertain malignancy 
potential was 1.0% (n = 6).  
This study had several limitations. It was 
designed retrospectively and must be supported 
with prospective studies. Also, the anamnesis 
of the patients and other comorbid diseases 
could not be evaluated in detail because the 
study was conducted retrospectively. 
As a result, TC covers a wide range of diseases 
that have varying prognoses. Many patients 
with this disease have excellent overall survival 
rates. It is increasing in our country at similar 
rates in accordance with the literature parallel 
to the worldwide increase. It was shown in the 
present study that it is detected more frequently 
in women with a similar histopathological 
distribution. 
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